Tiziana Life Sciences (NASDAQ:TLSA) Stock Rating Raised to Sell at Wall Street Zen

Key Points

• Wall Street Zen upgraded Tiziana Life Sciences from “strong sell” to “sell,” while analysts’ overall consensus remains “Hold,” with one Buy, one Hold, and one Sell rating.
• TLSA shares opened at $0.95, down 5%, with a 52-week range of $0.76 to $2.10; the stock’s 50-day and 200-day moving averages were $1.03 and $1.15, respectively.
• Insiders have been buying shares, including CEO Ivor Elrifi’s purchase of 667,000 shares for $667,000. Insiders own 39.82% of the company, which is developing foralumab-based therapies for neuroinflammatory and other immune-related diseases.

Tiziana Life Sciences (NASDAQ:TLSA - Get Free Report) was upgraded by Wall Street Zen from a "strong sell" rating to a "sell" rating in a report released on Saturday, Wall Street Zen reports.

Several other equities research analysts have also recently weighed in on TLSA. Zacks Research raised shares of Tiziana Life Sciences to a "hold" rating in a research report on Tuesday, July 14th. BTIG Research restated a "buy" rating on shares of Tiziana Life Sciences in a research report on Tuesday, September 22nd. Finally, Weiss Ratings upgraded shares of Tiziana Life Sciences from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold".

Tiziana Life Sciences Stock Down 5.0%

Shares of NASDAQ TLSA opened at $0.95 on Friday. Tiziana Life Sciences has a 52 week low of $0.76 and a 52 week high of $2.10. The firm's fifty day moving average is $1.03 and its 200 day moving average is $1.15.

Insider Buying and Selling

In related news, CEO Ivor Elrifi acquired 667,000 shares of the firm's stock in a transaction on Monday, August 3rd. The stock was acquired at an average cost of $1.00 per share, for a total transaction of $667,000.00. Following the acquisition, the chief executive officer owned 4,472,261 shares of the company's stock, valued at $4,472,261. This trade represents a 17.53% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders have acquired 988,423 shares of company stock valued at $985,909. 39.82% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tiziana Life Sciences

An institutional investor recently raised its position in Tiziana Life Sciences stock. Zhang Financial LLC increased its stake in Tiziana Life Sciences Ltd (NASDAQ:TLSA - Free Report) by 12.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 111,900 shares of the company's stock after buying an additional 12,000 shares during the period. Zhang Financial LLC owned 0.09% of Tiziana Life Sciences worth $131,000 at the end of the most recent reporting period.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing therapies that regulate the immune system and address inflammatory and neurodegenerative diseases. The company's research centers on treatments designed to modulate immune responses without broadly suppressing immune function.

Tiziana's lead product candidate is foralumab, a fully human monoclonal antibody that targets the CD3 receptor on T cells. The company is developing an intranasal formulation of foralumab for conditions associated with neuroinflammation, including non-active secondary progressive multiple sclerosis and Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.